Section Arrow
Quote
ANIP.NASDAQ
- ANI Pharmaceuticals
Quotes are at least 15-min delayed:2026/08/14 05:31 EDT
Pre Market
Last
 75.1
+0.33 (+0.44%)
Bid
30.28
Ask
82.8
High 77 
Low 74.77 
Volume 2.01K 
Regular Hours (Closed)
Last
 74.77
-0.345 (-0.46%)
Day High 
75.745 
Prev. Close
75.115 
1-M High
83.21 
Volume 
330.21K 
Bid
30.28
Ask
82.8
Day Low
74 
Open
75.48 
1-M Low
73.27 
Market Cap 
1.73B 
Currency 美元 
P/E 16.36 
%Yield -- 
10-SMA 78.51 
20-SMA 78.9 
50-SMA 80.68 
52-W High 99.5 
52-W Low 70.15 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
4.59/9.97
Enterprise Value
2.33B
Balance Sheet
Book Value Per Share
26.00
Cash Flow
Cash Flow Yield
0.11
Income Statement
Total Revenue
883.37M
Operating Revenue Per Share
19.56
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
VTRSViatris16.04-0.06-0.37%-- 
Pre Market 16.1 +0.06 +0.37%
CPHIChina Pharma Holdings Inc1.09-0.06-5.22%-- 
Pre Market 1.01 -0.08 -7.34%
HIMSHims & Hers Health28.77-1.2-4.00%-- 
Pre Market 29.03 +0.26 +0.90%
AKANAkanda Corp.5.01-0.38-7.05%-- 
Pre Market 8.8 +3.79 +75.65%
TEVATeva Pharmaceutical Industries Limited36.52-0.22-0.60%61.23PE
Pre Market 36.5 -0.02 -0.05%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology,rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically,it generates maximum revenue from the United States, followed by other markets.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.